Corcept Shares Rise More Than 45% in Six Months: Here's Why

Shares of Corcept Therapeutics Incorporated (CORT) have gained 46.2% in the past six months against the industry's decline of 2%. The company's sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. Factors Driving CORT Stock in the Given Time Frame Corcept has made steady progress ...